Combining expertise to advance precision
medicine, while enabling efficient and timely insights into the
diagnosis of rare diseases and hereditary cancer around the
world
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, and Centogene N.V. (Nasdaq: CNTG),
the essential life science partner for data-driven answers in rare
and neurodegenerative diseases, today announced the launch of three
next-generation sequencing (NGS) target enrichment panels to
support rare disease and hereditary cancer research and support
diagnostics.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230110005063/en/
Target enrichment panels enable more in-depth sequencing on
target genes, reducing the need for comprehensive sequencing. This
allows for more sensitive detection of target genetic sequences and
provides higher confidence that variants will be detected, further
driving the understanding of diseases and supporting healthcare
professionals in providing precision medicine.
Labs and research institutions can purchase these ready-made
panels to help accelerate their research, and also have the option
of using CENTOGENE’s CentoCloud® for the identification,
prioritization, and classification of human genetic variants to
expedite diagnostic analysis.
“There are over 7,000 rare diseases impacting over 350 million
patients, many of whom are not diagnosed until the late stages of
the disease. Our mission is to provide data-driven, life-changing
answers as early as possible to ultimately accelerate the
development of treatments,” said Kim Stratton, Chief Executive
Officer at CENTOGENE. “By partnering with Twist to develop these
custom panels, we are enabling access to diagnostics and generating
novel insights for the medical community, fueled by
multidimensional data from the CENTOGENE Biodatabank.”
All three new Alliance Panels are highly curated using the
CENTOGENE Biodatabank, with nearly 700,000 patients represented
from over 120 highly diverse countries, over 70% of whom are of
non-European descent. Identified sequences are then synthesized by
Twist as biotinylated capture probes which are compatible with
Twist’s library preparation solution and target enrichment
workflows. The panels offered through Twist will include:
- The Twist Alliance CNTG Exome Panel, which enables whole exome
analysis of genetic markers relevant to rare diseases.
- The Twist Alliance CNTG Rare Disease Panel, which offers
analysis of focused rare-disease-related sequences.
- The Twist Alliance CNTG Hereditary Oncology Panel, which
enables the detection of biomarkers that indicate a high risk of
developing cancer.
“Twist Alliance panels enable research by providing access to
expert-developed panels tailored to specific research areas.
CENTOGENE brings highly curated expertise and data in rare
diseases, an important complement to our existing Alliance panels,”
said Emily M. Leproust, Ph.D., CEO and co-founder of Twist
Bioscience. “As we expand our offering of Alliance panels, we
believe it is critical to offer expert-developed content in an
off-the-shelf format, compatible with Twist’s extended custom panel
offering, enabling a wider user base for these important
tools.”
For inquiries about the Twist Alliance CNTG panels please visit:
https://www.twistbioscience.com/contact.
About Twist Alliance CNTG Exome
Twist Alliance CNTG Exome is designed using Twist’s core exome
and reference sequencing, a full mitochondrial genome and exclusive
content for enhanced coverage of relevant genes and variants
related to rare diseases.
About Twist Alliance CNTG Rare Disease Panel
The Twist Alliance CNTG Rare Disease Panel includes more than
2,500 relevant rare disease-associated genes and covers ≥99.5% of
targeted regions, offering researchers a more lightweight tool for
capturing the crucial rare disease coverage in the CNTG Exome
without the full footprint. This panel can be used to detect genes
associated with but not limited to rare treatable diseases, early
onset childhood disorders, cardiac disorders, neurodegenerative
diseases, skeletal abnormalities and metabolic disorders.
About Twist Alliance CNTG Hereditary Oncology Panel
The Twist Alliance CNTG Hereditary Oncology Panel includes 72
selected cancer-associated genes and covers ≥99.5% of targeted
regions. The panel can be used to identify genetic predisposition
to hereditary tumors including breast cancer, gastrointestinal
tumors, Li-Fraumeni syndrome, MEN1, MEN2, paragangliomas and
others.
About Twist Alliance Panels
In partnership with leading research institutions from around
the world, Twist has curated a collection of high-quality target
enrichment panels for applications ranging from carrier screening
to cancer diagnostics and whole exome sequencing. The Twist
Alliance Panels combine the strengths of precise, highly uniform
oligonucleotide synthesis with the specialty expertise of leading
scientific research partners.
Well-designed, custom target enrichment panels enable increased
sequencing depth on target genes while reducing overall sequencing.
This allows for more sensitive detection of target sequences and
higher confidence variant detection.
About CentoCloud
CentoCloud is a cloud-based Software as a Service (SaaS)
platform specifically designed for the rapid bioinformatic analysis
and interpretation of next-generation sequencing (NGS) data based
on the proprietary CENTOGENE Biodatabank and external reference
databases. It allows for the identification, prioritization, and
classification of human genetic variants associated with
genetic/inherited diseases.
The fully automated bioinformatics pipeline analyzes NGS data
based on CENTOGENE's validated testing products provided by Twist
Bioscience.
Powered by an end-to-end workflow with best-in-class
bioinformatics as well as CENTOGENE's medical reporting service,
CentoCloud encompasses the latest diagnostic insights – allowing
physicians around the world to provide state-of-the-art
individualized patient care, no matter where they are located.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
About CENTOGENE
CENTOGENE’s mission is to provide data-driven, life-changing
answers to patients, physicians, and pharma companies for rare and
neurodegenerative diseases. We integrate multiomic technologies
with the CENTOGENE Biodatabank – providing dimensional analysis to
guide the next generation of precision medicine. Our unique
approach enables rapid and reliable diagnosis for patients,
supports a more precise physician understanding of disease states,
and accelerates and de-risks targeted pharma drug discovery,
development, and commercialization.
Since our founding in 2006, CENTOGENE has been offering rapid
and reliable diagnosis – building a network of approximately 30,000
active physicians. Our ISO, CAP, and CLIA certified multiomic
reference laboratories in Germany utilize Phenomic, Genomic,
Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets.
This data is captured in our CENTOGENE Biodatabank, with nearly
700,000 patients represented from over 120 highly diverse
countries, over 70% of whom are of non-European descent. To date,
the CENTOGENE Biodatabank has contributed to generating novel
insights for more than 260 peer-reviewed publications.
By translating our data and expertise into tangible insights, we
have supported over 50 collaborations with pharma partners.
Together, we accelerate and de-risk drug discovery, development,
and commercialization in target & drug screening, clinical
development, market access and expansion, as well as offering
CENTOGENE Biodatabank Licenses and Insight Reports to enable a
world healed of all rare and neurodegenerative diseases.
To discover more about our products, pipeline, and
patient-driven purpose, visit www.centogene.com and follow us on
LinkedIn.
Twist Bioscience Legal Notice Regarding Forward-Looking
Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, statements regarding the
ability of the Twist Alliance CNTG Exome Panel to enable whole
exome analysis of genetic markers relevant to rare diseases; the
ability of the Twist Alliance CNTG Rare Disease Panel to offer
analysis of focused rare-disease-related sequences; and the ability
of the Twist Alliance CNTG Hereditary Oncology Panel to enable the
detection of biomarkers that indicate a high risk of developing
cancer. Forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause Twist
Bioscience’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
risks and uncertainties relating to COVID-19; the ability to
attract new customers and retain and grow sales from existing
customers; risks and uncertainties of rapidly changing technologies
and extensive competition in synthetic biology that could make the
products Twist Bioscience is developing obsolete or
non-competitive; uncertainties of the retention of significant
customers; the ability of Twist Bioscience to successfully
integrate acquired companies, including Abveris, and to achieve
expected benefits from acquisitions; supply chain and other
disruptions caused by the COVID-19 pandemic or otherwise; risks of
third party claims alleging infringement of patents and proprietary
rights or seeking to invalidate Twist Bioscience’s patents or
proprietary rights; and the risk that Twist Bioscience’s
proprietary rights may be insufficient to protect its technologies.
For a description of the risks and uncertainties that could cause
actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Annual Report on Form 10-K
filed with the Securities and Exchange Commission on November 28,
2022 and subsequent filings with the SEC. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Twist Bioscience specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
CENTOGENE Legal Notice Regarding Forward-Looking
Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. federal securities laws. Statements
contained herein that are not clearly historical in nature are
forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” and similar
expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” are
generally intended to identify forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause
CENTOGENE’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward- looking
statements. Such risks and uncertainties include, among others,
negative economic and geopolitical conditions and instability and
volatility in the worldwide financial markets, possible changes in
current and proposed legislation, regulations and governmental
policies, pressures from increasing competition and consolidation
in our industry, the expense and uncertainty of regulatory
approval, including from the U.S. Food and Drug Administration, our
reliance on third parties and collaboration partners, including our
ability to manage growth, execute our business strategy and enter
into new client relationships, our dependency on the rare disease
industry, our ability to manage international expansion, our
reliance on key personnel, our reliance on intellectual property
protection, fluctuations of our operating results due to the effect
of exchange rates, our ability to streamline cash usage, our
continued ongoing compliance with covenants linked to financial
instruments, our requirement for additional financing, or other
factors. For further information on the risks and uncertainties
that could cause actual results to differ from those expressed in
these forward-looking statements, as well as risks relating to
CENTOGENE’s business in general, see CENTOGENE’s risk factors set
forth in CENTOGENE’s Form 20-F filed on March 31, 2022, with the
Securities and Exchange Commission (the “SEC”) and subsequent
filings with the SEC. Any forward-looking statements contained in
this press release speak only as of the date hereof, and
CENTOGENE’s specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230110005063/en/
Twist Bioscience Angela Bitting SVP, Corporate Affairs
925- 202-6211 abitting@twistbioscience.com
CENTOGENE Ben Legg Corporate Communications
Press@centogene.com
Lennart Streibel Investor Relations IR@centogene.com
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Sep 2023 to Sep 2024